Print Page  |  Close Window

Overview

BioTelemetry provides cardiac monitoring services, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. Since the Company became focused on cardiac monitoring in 1999, the Company has developed a proprietary integrated patient management platform that incorporates a wireless data transmission network, Food and Drug Administration ("FDA") cleared algorithms and medical devices, and 24-hour digital monitoring service centers.

The Company operates under three segments: patient services, product and research services. The patient services segment is focused on the diagnosis and monitoring of cardiac arrhythmias, or heart rhythm disorders. The Company provides cardiologists and electrophysiologists who prefer to use a single source of cardiac monitoring services with a full spectrum of solutions, ranging from the differentiated Mobile Cardiac Outpatient TelemetryTM ("MCOT™") service to wEvent, event, Holter, Pacemaker and International normalized ratio ("INR") monitoring. INR monitoring is a measurement of blood coagulation in the circulatory system and is prescribed for patients on long term anticoagulation therapy. The product business segment focuses on the development, manufacturing, testing and marketing of medical devices to medical companies, clinics and hospitals. The research services segment is engaged in central core laboratory services providing cardiac monitoring, scientific consulting and data management services for drug and medical device trials.

Recent NewsMore >>
DateTitle 
08/08/17BioTelemetry, Inc. Reports Second Quarter 2017 Financial Results
Reports Record Quarterly Revenue and EBITDA   Raises Full Year 2017 Guidance MALVERN, Pa., Aug. 08, 2017 (GLOBE NEWSWIRE) -- BioTelemetry, Inc. (NASDAQ:BEAT), the leading wireless medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, today reported results for the second quarter ended June 30, 2017. Company Highlights Recognized highest quarterly revenue in Company’s history of $58.1 million, a 10.3% increase over... 
Printer Friendly Version
07/31/17BioTelemetry, Inc. to Release Second Quarter 2017 Earnings Results on August 8, 2017
MALVERN, Pa., July 31, 2017 (GLOBE NEWSWIRE) -- BioTelemetry, Inc. (NASDAQ:BEAT) will release its second quarter 2017 earnings on Tuesday, August 8 at 4:00 PM Eastern Time. The BioTelemetry quarterly conference call will be held at 5:00 PM Eastern Time, Tuesday, August 8, 2017.  The broadcast will be available through the investor information section of the BioTelemetry website www.gobio.com.  If you are unable to participate during the live webcast, an archive will be available on our webs... 
Printer Friendly Version
07/12/17BioTelemetry, Inc. Completes LifeWatch AG Acquisition
Deal Solidifies BioTelemetry’s Leadership Position in Remote Cardiac Monitoring MALVERN, Pa. and ZUG, Switzerland, July 12, 2017 (GLOBE NEWSWIRE) -- BioTelemetry, Inc. (NASDAQ:BEAT), the world’s leading wireless medical technology company focused on the delivery of health information for healthcare providers to monitor and diagnose patients accurately and cost-effectively, announces it has completed its acquisition of LifeWatch AG (SIX:LIFE).  “We are gratified that LifeWatch AG shareholde... 
Printer Friendly Version
07/07/17BioTelemetry, Inc. Reaches a Final Milestone in Acquisition of LifeWatch AG
MALVERN, Pa. and ZUG, Switzerland, July 07, 2017 (GLOBE NEWSWIRE) -- BioTelemetry, Inc. (NASDAQ:BEAT), the leading wireless medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, announced today the definitive results of the tender offer for LifeWatch AG (SIX:LIFE) which concluded on June 28, 2017.  The definitive results show shareholders have tendered 17,848,661 shares of LifeWatch, representing approximately 97% of the to... 
Printer Friendly Version

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.